Navigation Links
Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status
Date:11/23/2007

PRINCETON, N.J., and PARIS, Nov. 23 /PRNewswire-FirstCall/ -- Bristol- Myers Squibb Company (NYSE: BMY) and Pierre Fabre Medicament reported today that they are terminating their license agreement for the development of vinflunine, a chemotherapy agent under investigation for the treatment of advanced or metastatic bladder cancer and other tumor types. Vinflunine was developed by Pierre Fabre Medicament and licensed to Bristol-Myers Squibb in 2004 for specific territories. Based on a review of the clinical development program and the decision not to file a new drug application for bladder cancer in the United States, coupled with an analysis of Bristol-Myers Squibb's Research & Development priorities, the companies have jointly decided that all rights licensed to Bristol-Myers Squibb for vinflunine will be returned to Pierre Fabre Medicament.

"In Europe, Pierre Fabre Medicament intend to continue discussions with regulatory authorities and plan to file for the registration of vinflunine for bladder cancer in the first quarter of 2008," said P. Hurteloup, General Manager of Pierre Fabre Medicament Oncology Division. "We also are considering a range of further development options, including pursuing the product on a worldwide basis for the treatment of a number of cancers."

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

Pierre Fabre Medicament is a French private group dedicated to consumers and patients from health to beauty.


'/>"/>
SOURCE Bristol-Myers Squibb Company; Pierre Fabre Medicament
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
2. Bristol-Myers Squibb to Acquire Adnexus Therapeutics
3. Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
4. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
5. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
6. CardioDynamics Provides 2007 Shareholder Meeting Update
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
9. Reed Group to Provide MDA Internet Disability Duration Guidelines to U.S. Navy
10. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
11. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its 4th ... in San Francisco, CA. The Summit brings together current and former FDA office bearers, ... and government officials from around the world to address key issues in device compliance, ...
(Date:10/11/2017)... 11, 2017  VMS BioMarketing, a leading provider of patient ... Clinical Nurse Educator (CNE) network, which will launch this week. ... among health care professionals to enhance the patient care experience ... and other health care professionals to help women who have ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the main ... people each year. Especially those living in larger cities are affected by air pollution ... of the most pollution-affected countries globally - decided to take action. , “I knew ...
(Date:10/11/2017)... Florida (PRWEB) , ... October 11, 2017 , ... ... Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 ... for the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane ...
Breaking Biology Technology:
(Date:4/24/2017)... , April 24, 2017 Janice ... partner with  Identity Strategy Partners, LLP (IdSP) , ... or without President Trump,s March 6, 2017 ... Entry , refugee vetting can be instilled with greater ... (Right now, all refugee applications are suspended by ...
(Date:4/13/2017)... SANTA MONICA, Calif. , April 13, 2017 /PRNewswire/ ... New York will feature emerging and ... Innovation Summits. Both Innovation Summits will run alongside the ... variety of speaker sessions, panels and demonstrations focused on ... east coast,s largest advanced design and manufacturing event will ...
(Date:4/11/2017)... 11, 2017 No two people are ... the New York University Tandon School of Engineering ... found that partial similarities between prints are common ... mobile phones and other electronic devices can be ... vulnerability lies in the fact that fingerprint-based authentication ...
Breaking Biology News(10 mins):